The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The ...

During an AIS, brain damage occurs and progresses rapidly ... trial compared TNKase to Activase in treating patients with acute ischemic stroke that presented with a disabling neurological ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to ...

Stroke is defined as an "acute neurologic dysfunction ... 2003). When an ischemic stroke occurs, the blood supply to the brain is interrupted, and brain cells are deprived of the glucose and ...

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The findings suggest that the treatment may work as an add-on therapy to standard ...

Stroke, (paralysis) or a brain attack is a disabling brain disorder that affects more than 20 million people across the world ...

Researchers at UT Southwestern Medical Center found that tenecteplase, a newer drug, is just as safe and effective as ...

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute ...